|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
35,915,000 |
Market
Cap: |
4.57(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$36.74 - $124.44 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile TransMedics Group is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across various disease states. Co. has developed the Organ Care System (OCS), a portable organ perfusion and monitoring system that using Co.'s technology to replicate near-physiologic conditions for donor organs outside of the human body. The OCS was designed to perfuse donor organs with warm, oxygenated and nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. Co.'s OCS products are one for each of lung, heart and liver transplantations.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
2,500 |
2,500 |
Total Buy Value |
$0 |
$0 |
$155,000 |
$155,000 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
271,054 |
342,899 |
405,806 |
1,060,395 |
Total Sell Value |
$27,491,657 |
$33,196,965 |
$37,923,912 |
$74,654,923 |
Total People Sold |
4 |
6 |
6 |
10 |
Total Sell Transactions |
21 |
30 |
40 |
119 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Khayal Tamer I |
Chief Commercial Officer |
|
2023-01-18 |
4 |
AS |
$65.11 |
$84,643 |
D/D |
(1,300) |
1,300 |
|
13% |
|
Khayal Tamer I |
Chief Commercial Officer |
|
2023-01-18 |
4 |
OE |
$16.00 |
$20,800 |
D/D |
1,300 |
2,600 |
|
- |
|
Hassanein Waleed H |
President & CEO |
|
2023-01-17 |
4 |
AS |
$64.14 |
$481,050 |
D/D |
(7,500) |
418,785 |
|
11% |
|
Gordon Stephen |
Chief Financial Officer |
|
2023-01-17 |
4 |
AS |
$60.12 |
$300,600 |
D/D |
(5,000) |
5,714 |
|
11% |
|
Gordon Stephen |
Chief Financial Officer |
|
2023-01-17 |
4 |
OE |
$16.14 |
$80,700 |
D/D |
5,000 |
10,714 |
|
- |
|
Carey John F |
VP of Operations |
|
2023-01-17 |
4 |
AS |
$60.72 |
$88,425 |
D/D |
(1,410) |
14,120 |
|
11% |
|
Carey John F |
VP of Operations |
|
2023-01-17 |
4 |
OE |
$38.46 |
$54,229 |
D/D |
1,410 |
15,530 |
|
- |
|
Khayal Tamer I |
Chief Commercial Officer |
|
2023-01-13 |
4 |
AS |
$60.20 |
$355,180 |
D/D |
(5,900) |
1,300 |
|
18% |
|
Khayal Tamer I |
Chief Commercial Officer |
|
2023-01-13 |
4 |
OE |
$16.00 |
$94,400 |
D/D |
5,900 |
7,200 |
|
- |
|
Khayal Tamer I |
Chief Commercial Officer |
|
2023-01-03 |
4 |
AS |
$60.93 |
$253,605 |
D/D |
(4,100) |
1,300 |
|
33% |
|
Khayal Tamer I |
Chief Commercial Officer |
|
2023-01-03 |
4 |
OE |
$16.00 |
$65,600 |
D/D |
4,100 |
5,400 |
|
- |
|
Damme Laura |
VP, Clinical Affairs |
|
2022-12-15 |
4 |
S |
$58.96 |
$294,475 |
D/D |
(4,990) |
0 |
|
-32% |
|
Damme Laura |
VP, Clinical Affairs |
|
2022-12-15 |
4 |
OE |
$38.46 |
$191,915 |
D/D |
4,990 |
4,740 |
|
- |
|
Damme Laura |
VP, Clinical Affairs |
|
2022-12-14 |
4 |
S |
$62.43 |
$371,271 |
D/D |
(5,947) |
0 |
|
-31% |
|
Damme Laura |
VP, Clinical Affairs |
|
2022-12-14 |
4 |
OE |
$38.46 |
$228,722 |
D/D |
5,947 |
5,947 |
|
- |
|
Provost Miriam |
VP, Global Regulatory Affairs |
|
2022-12-13 |
4 |
S |
$62.24 |
$269,797 |
D/D |
(4,315) |
15,154 |
|
-36% |
|
Provost Miriam |
VP, Global Regulatory Affairs |
|
2022-12-13 |
4 |
OE |
$38.46 |
$227,606 |
D/D |
5,918 |
19,469 |
|
- |
|
Provost Miriam |
VP, Global Regulatory Affairs |
|
2022-12-09 |
4 |
S |
$59.00 |
$213,167 |
D/D |
(3,613) |
13,551 |
|
-51% |
|
Provost Miriam |
VP, Global Regulatory Affairs |
|
2022-12-09 |
4 |
OE |
$16.14 |
$171,500 |
D/D |
5,126 |
14,118 |
|
- |
|
Carey John F |
VP of Operations |
|
2022-12-05 |
4 |
OE |
$0.28 |
$10 |
D/D |
36 |
13,844 |
|
- |
|
Carey John F |
VP of Operations |
|
2022-12-02 |
4 |
AS |
$63.50 |
$635,000 |
D/D |
(10,000) |
13,808 |
|
3% |
|
Carey John F |
VP of Operations |
|
2022-12-02 |
4 |
OE |
$0.28 |
$388,250 |
D/D |
23,037 |
23,808 |
|
- |
|
Gordon Stephen |
Chief Financial Officer |
|
2022-12-01 |
4 |
AS |
$61.30 |
$613,026 |
D/D |
(10,000) |
5,714 |
|
14% |
|
Gordon Stephen |
Chief Financial Officer |
|
2022-12-01 |
4 |
OE |
$16.14 |
$161,400 |
D/D |
10,000 |
15,714 |
|
- |
|
Khayal Tamer I |
Chief Commercial Officer |
|
2022-12-01 |
4 |
OE |
$2.21 |
$24,423 |
I/I |
11,051 |
11,051 |
|
- |
|
358 Records found
|
|
Page 6 of 15 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|